Drug Profile
Rebimastat
Alternative Names: BMS 275291; D 2163Latest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Celltech Group
- Developer Bristol-Myers Squibb
- Class Antineoplastics; Hydantoins; Small molecules
- Mechanism of Action Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer; Cancer; Kaposi's sarcoma; Non-small cell lung cancer; Prostate cancer